1. Home
  2. Analysis
  3. Beovu
  4. Vitreous-disorder

Beovu and Vitreous disorder - a phase IV clinical study of FDA data

Summary:

Vitreous disorder is reported as a side effect among people who take Beovu (brolucizumab-dbll), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Eylea, and have High blood pressure.

The phase IV clinical study analyzes which people have Vitreous disorder when taking Beovu. It is created by eHealthMe based on reports of 3,872 people who have side effects when taking Beovu from the FDA, and is updated regularly.

What is Beovu?

Beovu has active ingredients of brolucizumab-dbll. eHealthMe is studying from 3,872 Beovu users. Check the latest studies of Beovu.

What is Vitreous disorder?

Vitreous disorder (eye disease) is found to be associated with 56 drugs and 184 conditions by eHealthMe. Check the latest studies of Vitreous disorder.

On Jul, 13, 2026

3,872 people reported to have side effects when taking Beovu.
Among them, 18 people (0.46%) have Vitreous disorder.

Could Beovu cause Vitreous disorder?

Among these 18 people:

How long have people been on Beovu when they have Vitreous disorder? *

  • < 1 month: 83.33 %
  • 1 - 6 months: 16.67 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Vitreous disorder when taking Beovu? *

  • female: 80 %
  • male: 20 %

What is the age of people who have Vitreous disorder when taking Beovu? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

What are other drugs people take besides Beovu? *

  1. Eylea: 6 people, 33.33%
  2. Lucentis: 4 people, 22.22%
  3. Cardizem: 2 people, 11.11%
  4. Tobradex: 1 person, 5.56%
  5. Spiriva: 1 person, 5.56%
  6. Singulair: 1 person, 5.56%
  7. Pantoprazole: 1 person, 5.56%
  8. Norvasc: 1 person, 5.56%
  9. Hctz: 1 person, 5.56%
  10. Eliquis: 1 person, 5.56%

What are other side effects people have besides Vitreous disorder? *

  1. Vitreous Floaters (spots before the eyes): 8 people, 44.44%
  2. Eye Inflammation: 7 people, 38.89%
  3. Visual Field Defect: 7 people, 38.89%
  4. Vision Blurred: 7 people, 38.89%
  5. Visual Impairment: 6 people, 33.33%
  6. Retinal Vasculitis (a sight-threatening inflammatory eye condition that involves the retinal vessels): 6 people, 33.33%
  7. Vitritis (inflammation of the vitreous humour of the eye): 5 people, 27.78%
  8. Blindness: 4 people, 22.22%
  9. Eye Haemorrhage (bleeding in the eye): 4 people, 22.22%
  10. Papilloedema (optic disc swelling): 4 people, 22.22%

What are the existing conditions these people have? *

  1. High Blood Pressure: 6 people, 33.33%
  2. Varicose Vein (veins that have become enlarged and tortuous): 4 people, 22.22%
  3. Choroidal Neovascularisation (creation of new blood vessels in vascular layer of eye): 1 person, 5.56%
  4. Age-Related Macular Degeneration: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Beovu and have Vitreous disorder?

- Check whether Vitreous disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Beovu:

Vitreous disorder treatments and more:

How severe was Vitreous disorder and when was it recovered:

Expand to all the drugs that have ingredients of brolucizumab-dbll:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Beovu:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Vitreous disorder:

Browse all the conditions that are associated with Vitreous disorder:

How the study uses the data?

The study uses data from the FDA. It is based on brolucizumab-dbll (the active ingredients of Beovu) and Beovu (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.